TNGX Q4 2023 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-15.3% YoY

Gross Profit

$5M100.0% margin

Operating Income

-$35M-644.7% margin

Net Income

-$31M-566.4% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

-49.4%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$28M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$403M

Total Liabilities

$149M

Stockholders' Equity

$253M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$6M	-15.3%
Gross Profit	$5M	$5M	+9.5%
Operating Income	-$35M	-$31M	-14.5%
Net Income	-$31M	-$29M	-5.9%

Revenue Segments

Collaboration Revenue

$11M100%